Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tolerability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,028 result(s) found for: Tolerability. Displaying page 10 of 702.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    EudraCT Number: 2014-002741-21 Sponsor Protocol Number: AAA-Ga-TOC-EU-01 Start Date*: 2014-10-23
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Medical condition: Patients with proven gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000734-35 Sponsor Protocol Number: TV48125-CNS-10141 Start Date*: 2019-07-25
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous administration of Fremanezumab in Pediatric Migraine Patients (6 to 11 Years of Age ...
    Medical condition: Prevention of migraine
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004720-11 Sponsor Protocol Number: AV-X-03 Start Date*: 2014-02-11
    Sponsor Name:ALK-Abelló, S.A.
    Full Title: An open trial to assess the tolerability of AVANZ® Cupressus immunotherapy
    Medical condition: Allergic rhinoconjunctivitis induced by Cupressus arizonica pollen.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004798-99 Sponsor Protocol Number: 0903010259 Start Date*: 2013-02-27
    Sponsor Name:Weill Medical College of Cornell University
    Full Title: Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS)
    Medical condition: Familial amyotrophic lateral sclerosis (FALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10036704 Primary lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000701-13 Sponsor Protocol Number: ISIS494372-CS3 Start Date*: 2014-08-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously t...
    Medical condition: High Lipoprotein(a)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022891 - Investigations 10054009 Lipoprotein (a) increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002801-22 Sponsor Protocol Number: X100 Start Date*: 2006-08-18
    Sponsor Name:The Royal Marsden NHSF Trust
    Full Title: Carboplatin Plus Xeloda Followed By Maintenance Xeloda (CARBOX)
    Medical condition: relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    6 10026662
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000175-27 Sponsor Protocol Number: CSLCT-USF-10-69 Start Date*: 2015-03-23
    Sponsor Name:bioCSL Pty Ltd
    Full Title: A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL’s Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Yea...
    Medical condition: Influenza, human
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002728-17 Sponsor Protocol Number: GRC17536-204 Start Date*: 2013-09-24
    Sponsor Name:Glenmark Pharmaceuticals SA
    Full Title: A Phase 2a, Multi-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Inhaled GRC 17536, Administered for 4 Weeks, in Patient...
    Medical condition: Refractory Chronic Cough.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003386-22 Sponsor Protocol Number: PRX302-2-07 Start Date*: 2015-01-19
    Sponsor Name:Sophiris Bio Corp
    Full Title: A Single Centre, Open Label, Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Signific...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001259-22 Sponsor Protocol Number: 1160.105 Start Date*: 2014-08-05
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 yea...
    Medical condition: venous thrombotic event
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000050-18 Sponsor Protocol Number: MK-0518-248 Start Date*: 2017-01-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination with Other Antiretroviral Agents to Evaluate the Safety, Tolerability, an...
    Medical condition: Human immunodeficiency virus infection
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005549-35 Sponsor Protocol Number: E10030-02 Start Date*: 2014-04-10
    Sponsor Name:Barcelona Macula Foundation Research for Vision
    Full Title: An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of FovistaTM (Anti-PDGF...
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10071129 Neovascular age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001391-37 Sponsor Protocol Number: B2C110165 Start Date*: 2007-08-14
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic...
    Medical condition: COPD patients (moderate)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000326-70 Sponsor Protocol Number: R076477-SCH-302/702 Start Date*: 2004-08-11
    Sponsor Name:Janssen-Cilag, Johnson & Johnson spol. s.r.o.
    Full Title: A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliper...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-004555-30 Sponsor Protocol Number: 1903-004 Start Date*: 2009-04-28
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK-1903 in Patients with Dyslipidemia
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004410-29 Sponsor Protocol Number: V72P10 Start Date*: 2014-10-27
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l
    Full Title: A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged ...
    Medical condition: Prophylaxis against invasive meningococcal disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023980-17 Sponsor Protocol Number: Metformin 3.0 Start Date*: 2011-08-24
    Sponsor Name:St. Antonius Hospital
    Full Title: An efficacy, safety and pharmacokinetic study on the short-term and long-term use of METFORMIN in obese children and adolescents
    Medical condition: obese children and adolescents of Caucasian descent with insulin resistance in the age of ≥ 10 and ≤ 16 years at study entry.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003121-42 Sponsor Protocol Number: CHDR1635 Start Date*: 2019-11-28
    Sponsor Name:Enceladus Pharmaceuticals BV
    Full Title: A Phase I-IIa, Open label, Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate as Monotherapy in Pa...
    Medical condition: Castration resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004776-56 Sponsor Protocol Number: AT1-2017 Start Date*: 2019-03-06
    Sponsor Name:Arctic Therapeutics ehf
    Full Title: Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study
    Medical condition: Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000734-36 Sponsor Protocol Number: SPD476-303 Start Date*: 2005-07-13
    Sponsor Name:Shire Pharmaceutical Development Inc.
    Full Title: A phase III, randomized, multi-center, open-label, 12 to 14 months extension study to evaluate the safety and tolerability of SPD476 (mesalazine) give once daily vs. twice daily for the maintenance...
    Medical condition: Subject not in remission of Ulcerative Colitis (UC-DAI score of >1) at the End of Study/Early Withdrawal Visit of Study 301 or 302. Subject in remission of UC (UC-DAI<1 with a score of 0 for rectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:11:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA